Evidence map›Paper›PMID 34721732›Full record

ArticleDisease markers2021

Identification and Validation of a Proliferation-Associated Score Model Predicting Survival in Lung Adenocarcinomas.

Yunyi Bian, Qihai Sui, Guoshu Bi, Yuansheng Zheng, Mengnan Zhao, Guangyu Yao, Liang Xue, Yi Zhang, Hong Fan

Open access · hybridAbstract readValidation Study
In one paragraph

Article in Disease markers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Yunyi BianDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.ORCID https://orcid.org/0000-0003-3864-1199
Qihai SuiDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Guoshu BiDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Yuansheng ZhengDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Mengnan ZhaoDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Guangyu YaoDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Liang XueDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Yi ZhangDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.ORCID https://orcid.org/0000-0002-3306-3169
Hong FanDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.ORCID https://orcid.org/0000-0002-2005-1150
Sun Yat-sen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimThis study is aimed at building a risk model based on the genes that significantly altered the proliferation of lung adenocarcinoma cells and exploring the underlying mechanisms.

methodsThe data of 60 lung adenocarcinoma cell lines in the Cancer Dependency Map (Depmap) were used to identify the genes whose knockout led to dramatical acceleration or deacceleration of cell proliferation. Then, univariate Cox regression was performed using the survival data of 497 patients with lung adenocarcinoma in The Cancer Genome Atlas (TCGA). The least absolute shrinkage and selection operator (LASSO) model was used to construct a risk prediction score model. Patients with lung adenocarcinoma from TCGA were classified into high- or low-risk groups based on the scores. The differences in clinicopathologic, genomic, and immune characteristics between the two groups were analyzed. The prognosis of the genes in the model was verified with immunohistochemical staining in 100 samples from the Department of Thoracic Surgery, Zhongshan Hospital, and the alteration in the proliferation rate was checked after these genes were knocked down in lung adenocarcinoma cells (A549 and H358).

resultsA total of 55 genes were found to be significantly related to survival by combined methods, which were crucial to tumor progression in functional enrichment analysis. A six-gene-based risk prediction score, including the proteasome subunit beta type-6 (PSMB6), the heat shock protein family A member 9 (HSPA9), the deoxyuridine triphosphatase (DUT), the cyclin-dependent kinase 7 (CDK7), the polo-like kinases 1 (PLK1), and the folate receptor beta 2 (FOLR2), was built using the LASSO method. The high-risk group classified with the score model was characterized by poor overall survival (OS), immune infiltration, and relatively higher mutation load. A total of 9864 differentially expressed genes and 138 differentially expressed miRNAs were found between the two groups. Also, a nomogram comparing score model, age, and the stage was built to predict OS for patients with lung adenocarcinoma. Using immunohistochemistry, the expression levels of PSMB6, HSPA9, DUT, CDK7, and PLK1 were found to be higher in lung adenocarcinoma tissues of patients, while the expression of FOLR2 was low, which was consistent with survival prediction. The knockdown of PSMB6 and HSPA9 by siRNA significantly downregulated the proliferation of A549 and H358 cells.

conclusionThe proposed score model may function as a promising risk prediction tool for patients with lung adenocarcinoma and provide insights into the molecular regulation mechanism of lung adenocarcinoma.

Indexed as

Cell ProliferationMutationNomogramsTranscriptomeAdenocarcinoma of LungAgedBiomarkers, TumorFemaleFollow-Up StudiesHumansLung NeoplasmsMaleMicroRNAsMiddle AgedPrognosisROC CurveBiomarkers, TumorMicroRNAs

Identifiers

PMID34721732
PMCPMC8554523
OpenAlexW3206731848

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.